The miRNA–Drug Resistance Connection: A New Era of Personalized Medicine Using Noncoding RNA Begins
2012; Future Medicine; Volume: 13; Issue: 12 Linguagem: Inglês
10.2217/pgs.12.121
ISSN1744-8042
Autores Tópico(s)Circular RNAs in diseases
ResumoPharmacogenomicsVol. 13, No. 12 EditorialThe miRNA–drug resistance connection: a new era of personalized medicine using noncoding RNA beginsPrasun J MishraPrasun J MishraCenter for Cancer Research, National Cancer Institute, National Institutes of Health,37 Convent Drive, Bethesda, MD 20892, USA. Published Online:11 Sep 2012https://doi.org/10.2217/pgs.12.121AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: diagnosisdiseasedrug resistanceepidemiologygenetic variationgenomic medicineindividualized medicinemicroRNAmiRNAmiRSNPmutationsncRNAnoncoding RNApersonalized medicinepharmacogenomicspolymorphismsprognosisReferences1 Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature422(6934),835–847 (2003).Crossref, Medline, CAS, Google Scholar2 Lander ES. Initial impact of the sequencing of the human genome. Nature470(7333),187–197 (2011).Crossref, Medline, CAS, Google Scholar3 Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science294(5543),862–864 (2001).Crossref, Medline, CAS, Google Scholar4 Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell9(3),189–198 (2006).Crossref, Medline, CAS, Google Scholar5 Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics8(12),1625–1627 (2007).Link, CAS, Google Scholar6 Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA104(33),13513–13518 (2007).Crossref, Medline, CAS, Google Scholar7 Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA99(24),15524–15529 (2002).Crossref, Medline, CAS, Google Scholar8 Calin GA, Liu CG, Sevignani C et al. microRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA101(32),11755–11760 (2004).Crossref, Medline, CAS, Google Scholar9 Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J. Clin. Invest.119(8),2119–2123 (2009).Medline, CAS, Google Scholar10 Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem.253(5),1357–1370 (1978).Crossref, Medline, CAS, Google Scholar11 Mishra PJ, Song B, Mishra PJ et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS ONE4(12),e8445 (2010).Crossref, Google Scholar12 Blower PE, Chung JH, Verducci JS et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther.7(1),1–9 (2008).Crossref, Medline, CAS, Google Scholar13 Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin. Cancer Res.14(24),8080–8086 (2008).Crossref, Medline, CAS, Google Scholar14 Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene28(46),4065–4074 (2009).Crossref, Medline, CAS, Google Scholar15 Kovalchuk O, Filkowski J, Meservy J et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther.7(7),2152–2159 (2008).Crossref, Medline, CAS, Google Scholar16 Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis13(10),1215–1222 (2008).Crossref, Medline, CAS, Google Scholar17 Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan–CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem.284(39),26533–26546 (2009).Crossref, Medline, CAS, Google Scholar18 Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol.111(3),478–486 (2008).Crossref, Medline, CAS, Google Scholar19 Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res.68(2),425–433 (2008).Crossref, Medline, CAS, Google Scholar20 Xia L, Zhang D, Du R et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer123(2),372–379 (2008).Crossref, Medline, CAS, Google Scholar21 Garofalo M, Quintavalle C, Di Leva G et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene27(27),3845–3855 (2008).Crossref, Medline, CAS, Google Scholar22 Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem.283(44),29897–29903 (2008).Crossref, Medline, CAS, Google Scholar23 Zhao JJ, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem.283(45),31079–31086 (2008).Crossref, Medline, CAS, Google Scholar24 Xin F, Li M, Balch C et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics25(4),430–434 (2009).Crossref, Medline, CAS, Google Scholar25 Zhu H, Wu H, Liu X et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol.76(5),582–588 (2008).Crossref, Medline, CAS, Google Scholar26 Eitan R, Kushnir M, Lithwick-Yanai G et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol. Oncol.114(2),253–259 (2009).Crossref, Medline, CAS, Google Scholar27 Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther.8(5),1055–1066 (2009).Crossref, Medline, CAS, Google Scholar28 DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol. Oncol.27(3),307–311 (2009).Crossref, Medline, CAS, Google Scholar29 Iorio MV, Casalini P, Piovan C et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res.69(6),2195–2200 (2009).Crossref, Medline, CAS, Google Scholar30 Li Y, Li W, Yang Y et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res.1286,13–18 (2009).Crossref, Medline, CAS, Google Scholar31 To KK, Robey RW, Knutsen T et al. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol. Cancer Ther.8(10),2959–2968 (2009).Crossref, Medline, CAS, Google Scholar32 Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol.75(6),1374–1379 (2009).Crossref, Medline, CAS, Google Scholar33 Roccaro AM, Sacco A, Chen C et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood113(18),4391–4402 (2009).Crossref, Medline, CAS, Google Scholar34 Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med.15(1),31–33 (2009).Crossref, Medline, CAS, Google Scholar35 Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics10(3),399–416 (2009).Link, CAS, Google Scholar36 Mishra PJ. MicroRNA polymorphisms: a giant leap towards personalized medicine. Per. Med.6(2),119–125 (2009).Link, CAS, Google Scholar37 Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle7(7),853–858 (2008).Crossref, Medline, CAS, Google Scholar101 Louis L'Amour quotes. http://thinkexist.com/quotation/there-will-come-a-time-when-you-believe/773800.htmlGoogle Scholar102 All about the Human Genome Project. www.genome.gov/10001772Google Scholar103 List of papers published in the new field of miRNA drug resistance. www.ncbi.nlm.nih.gov/pubmed?term=microrna%20drug%20resistanceGoogle ScholarFiguresReferencesRelatedDetailsCited ByCurrent paradigms in epigenetic anticancer therapeutics and future challengesSeminars in Cancer Biology, Vol. 83Targeting the microRNA binding domain of argonaute 2: rational inhibitor design and study of mutation effects on protein-ligand interaction3 December 2019 | Journal of Biomolecular Structure and Dynamics, Vol. 38, No. 16MicroRNA-221 and MicroRNA-222 in Common Human Cancers: Expression, Function, and Triggering of Tumor Progression as a Key Modulator2 May 2019 | Laboratory Medicine, Vol. 50, No. 4Emerging role of circulating microRNA in the diagnosis of human infectious diseases26 August 2018 | Journal of Cellular Physiology, Vol. 234, No. 2miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathwayExperimental and Molecular Pathology, Vol. 106miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via FynBiomedicine & Pharmacotherapy, Vol. 106Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network14 July 2018 | Molecular Oncology, Vol. 12, No. 9miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer CellsJournal of Immunology Research, Vol. 2018The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5pBiochemical Pharmacology, Vol. 145Mir-221/222 are promising targets for innovative anticancer therapy21 March 2016 | Expert Opinion on Therapeutic Targets, Vol. 20, No. 9MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC220 July 2016 | Oncotarget, Vol. 7, No. 33Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells27 May 2016 | Cancer Gene Therapy, Vol. 23, No. 8A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells29 February 2016 | Clinical Cancer Research, Vol. 22, No. 5Long Non-coding RNAs and Drug ResistanceAsian Pacific Journal of Cancer Prevention, Vol. 16, No. 18Tumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS Malignancies7 December 2015 | International Journal of Molecular Sciences, Vol. 16, No. 12Refugia and the evolutionary epidemiology of drug resistance1 November 2015 | Biology Letters, Vol. 11, No. 11Promoter demethylation of nuclear factor-erythroid 2-related factor 2 gene in drug-resistant colon cancer cells8 July 2015 | Oncology Letters, Vol. 10, No. 3Review of microRNA in osteosarcoma and chondrosarcoma26 April 2015 | Medical Oncology, Vol. 32, No. 6MicroRNA Technology and Small-Molecule DeliveryMicroRNAs as promising biomarkers in cancer diagnostics22 October 2014 | Biomarker Research, Vol. 2, No. 1Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis18 October 2014 | Expert Review of Molecular Diagnostics, Vol. 14, No. 8A Long Non-Coding RNA snaR Contributes to 5-Fluorouracil Resistance in Human Colon Cancer Cells31 July 2014 | Molecules and Cells, Vol. 37, No. 7Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance4 June 2014 | Frontiers in Genetics, Vol. 5Non-Coding RNAs in Muscle Dystrophies30 September 2013 | International Journal of Molecular Sciences, Vol. 14, No. 10Post-Transcriptional Controls by Ribonucleoprotein Complexes in the Acquisition of Drug Resistance20 August 2013 | International Journal of Molecular Sciences, Vol. 14, No. 8Micro RNA Polymorphisms15 April 2013 Vol. 13, No. 12 Follow us on social media for the latest updates Metrics Downloaded 525 times History Published online 11 September 2012 Published in print September 2012 Information© Future Medicine LtdKeywordsdiagnosisdiseasedrug resistanceepidemiologygenetic variationgenomic medicineindividualized medicinemicroRNAmiRNAmiRSNPmutationsncRNAnoncoding RNApersonalized medicinepharmacogenomicspolymorphismsprognosisFinancial & competing interests disclosureThis work was supported by the Intramural Research Program of the Center of Cancer Research, NCI, NIH. Author thanks Dr Glenn Merlino, Chief Laboratory of Cancer Biology and Genetics, National Cancer Institute, USA, for the critical review of the manuscript. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)